Arrhythmic complications of transcatheter aortic valve replacement

Transcatheter aortic valve replacement has reshaped the treatment of severe aortic stenosis, particularly in older patients who carry meaningful surgical risk. Over the past decade, Australian and international registries have documented rapid uptake, with structural heart programs in Sydney, Melbourne, and Brisbane performing thousands of procedures each year. As the community of interventional cardiologists and electrophysiologists continues to expand, attention has shifted from periprocedural mortality and stroke toward arrhythmic complications that can profoundly affect recovery, length of stay, and long-term quality of life.

These rhythm disturbances range from transient conduction block to persistent atrial fibrillation and, less commonly, life-threatening ventricular tachycardia. The interaction between a metallic prosthesis and the adjacent conduction system creates a unique electrophysiological substrate that differs markedly from surgical valve replacement. Understanding how often these events occur, why they arise, and how clinicians should respond has become a shared responsibility of cardiology teams and implanting physicians, and continues to draw collaborative review at national meetings.

The aim of this overview is to synthesise contemporary evidence, highlight clinically useful predictors of arrhythmia, and outline pragmatic management strategies relevant to Australian structural heart programs. Readers will find references to local practice patterns, reimbursement pathways, and multidisciplinary models of care, alongside international trial data and pathophysiological reasoning.

Incidence and contemporary epidemiology of post-TAVR arrhythmias

New-onset conduction disturbance remains the most frequent arrhythmic complication following transcatheter aortic valve replacement. Contemporary series report permanent pacemaker implantation in roughly 10% to 15% of patients overall, with rates approaching 20% in those receiving self-expanding valves. Data from the Australia and New Zealand TAVR registry mirror these international figures, although centre-to-centre variation reflects differences in implantation depth, valve generation, and pre-existing right bundle branch block.

Atrial fibrillation is equally relevant. Pre-existing atrial fibrillation affects a third or more of TAVR candidates in Australian practice, given the typical age and comorbidity profile. New-onset atrial fibrillation within the first 30 days occurs in 5% to 10% of patients without prior arrhythmia and is associated with longer hospitalisation and higher stroke risk. Ventricular arrhythmias and sudden cardiac death remain uncommon, but registries consistently identify a small subgroup of patients who deteriorate months after the index procedure, often in the setting of progressive conduction disease or ventricular dysfunction.

Pre-procedural arrhythmia prevalence shapes post-procedural risk. A substantial proportion of TAVR candidates present with atrial fibrillation, prior stroke, or chronic conduction disease, all of which influence both periprocedural monitoring intensity and discharge planning. The Australian experience, documented in published registry analyses, supports these international patterns while highlighting the value of standardised reporting.

Mechanisms linking valve implantation to conduction injury

The anatomical relationship between the aortic root and the conduction system explains most post-TAVR rhythm complications. The membranous interventricular septum, containing the bundle of His, sits immediately beneath the non-coronary and right coronary cusps. Radial force from a balloon-expanded or self-expanded prosthesis, particularly when implanted more than 4 to 6 millimetres below the annular plane, can produce direct mechanical injury, haematoma, or ischaemia of the AV node and left bundle branches.

Pre-existing conduction disease amplifies this vulnerability. Patients with right bundle branch block, significant PR prolongation, or bifascicular block carry an unusually high likelihood of high-grade AV block, and these features are commonly incorporated into contemporary risk calculators. Procedural factors such as balloon aortic valvuloplasty, post-dilation, and depth of implantation all modify the mechanical impact on the conduction system, which is why local Heart Team discussions at institutions such as Royal Prince Alfred Hospital now incorporate electrophysiology input before device selection is finalised.

Atrial fibrillation and supraventricular tachyarrhythmias after TAVR

Atrial fibrillation after transcatheter aortic valve replacement can reflect pre-existing substrate unmasked by haemodynamic stress, or new-onset arrhythmia triggered by inflammation, atrial stretch, or periprocedural volume shifts. Early post-procedural AF, occurring within the first 48 to 72 hours, frequently resolves spontaneously, yet the early stroke risk and haemodynamic compromise warrant close attention. Many Australian centres now employ continuous telemetry for at least the first 24 hours post-implant, with selective use of anticoagulation guided by CHA₂DS₂-VASc scores calculated using the patient's age, sex, and comorbidities.

Anticoagulation decisions require careful balancing. The CSANZ position on valvular AF recognises that bioprosthetic valves in the aortic position are not, on their own, an indication for vitamin K antagonist therapy, and direct oral anticoagulants are widely used in Australian practice. Rate and rhythm strategies follow standard algorithms, though the patient's frailty, left atrial size, and procedural course influence whether cardioversion, beta-blockade, or amiodarone is preferred.

Ventricular arrhythmias and sudden cardiac death risk

Ventricular arrhythmias after TAVR are uncommon but clinically significant when they occur. Registry analyses suggest an incidence of sustained ventricular tachycardia or ventricular fibrillation in the range of 1% to 3% during the index admission, with a smaller ongoing risk in long-term follow-up. The mechanisms are heterogeneous: ischaemia from coronary obstruction, reperfusion injury, electrolyte disturbance, and pre-existing scar from prior myocardial infarction all contribute.

Risk stratification is imperfect. Left ventricular ejection fraction below 30%, pre-existing scar on cardiac MRI, and prolonged QRS duration have all been associated with higher event rates. In Australian practice, decisions regarding implantable cardioverter-defibrillator therapy are made jointly by Heart Failure and Electrophysiology services, often in the months after the procedure when recovery of ventricular function can be reassessed. Primary prevention ICD implantation during the index admission is generally reserved for patients with clear secondary prevention indications or severely depressed left ventricular function unlikely to recover.

Risk stratification before the catheterisation suite

Pre-procedural risk stratification is central to managing arrhythmic complications. The electrocardiogram provides critical information. Pre-existing right bundle branch block, left bundle branch block, PR interval prolongation, and bifascicular block each independently predict post-TAVR conduction disturbance. Transthoracic echocardiography, including assessment of LVOT calcification and membranous septum length, adds anatomical information that helps predict mechanical interaction with the conduction system.

Multidisciplinary discussion remains the cornerstone of decision-making in Australian structural heart programs. Electrophysiology consultation is sought when pre-existing conduction disease raises concern about pacing dependence. The Australia and New Zealand TAVR registry has been instrumental in refining these predictive models and benchmarking outcomes. Patient counselling regarding the likelihood of pacemaker implantation, recovery trajectory, and rehabilitation expectations is documented as part of informed consent, particularly for those in regional and rural areas who travel to metropolitan centres such as St Vincent's in Sydney or The Royal Melbourne for their procedure. Recent special-issues of the Journal of Arrhythmia have brought together multidisciplinary perspectives on these questions.

Periprocedural monitoring and acute management

Periprocedural monitoring and acute management follow a structured pathway in most Australian centres. Continuous telemetry begins before sheath insertion and continues for at least 24 hours after valve deployment. Temporary transvenous pacing is used prophylactically in high-risk patients, particularly those with pre-existing right bundle branch block, and remains in situ until sustained stable rhythm is documented. New left bundle branch block appears in roughly 10% to 25% of cases and warrants extended monitoring, often with outpatient ambulatory ECG or loop recorder for 30 days.

When high-grade conduction block persists beyond 24 to 48 hours, permanent pacemaker implantation is considered. The Cardiac Society of Australia and New Zealand endorses a conservative approach to early implantation, given that a meaningful number of patients with new conduction disturbance recover over the first week. Ambulatory monitoring and provocative testing with electrophysiology study are used to guide timing, particularly when the clinical picture is ambiguous.

Long-term follow-up and pacing considerations

Long-term follow-up after TAVR requires ongoing attention to conduction system function. Patients who receive a permanent pacemaker face higher rates of right ventricular pacing, which can contribute to pacing-induced cardiomyopathy over time. Conduction system pacing, including His-bundle and left bundle branch area pacing, has emerged as a promising strategy, and several Australian electrophysiology laboratories now offer this as first-line therapy where anatomy permits.

Beyond pacing, follow-up protocols include surveillance for atrial fibrillation, particularly in patients with paroxysmal episodes detected on ambulatory monitoring. Cardiac rehabilitation, accessible through referral pathways that include the Royal Flying Doctor Service for remote communities, supports recovery and functional capacity. For clinicians seeking to remain current with evolving evidence, themed collections on structural heart disease and electrophysiology offer a convenient starting point.

Submit your TAVR and arrhythmia research to the Journal of Arrhythmia and help shape the next generation of evidence-based care.